Hanmi Pharmaceutical announced on July 18th that Jassen, a global pharmaceutical company, that it is developing the second global clinical phase of the Hanmi Pharmaceutical obesity and diabetes bio-drug HM12325A (Janssen code: JNJ-64565111).
Jassen said on Friday that it was enrolled in Clinical Trials (clinicaltrials.gov) in the United States on July 17th to evaluate the safety and efficacy of 188 patients with obesity.
HM12525A is a candidate for obesity and diabetes biotechnology to help both weight loss and blood sugar control.
Furthermore, Hanmi Pharmaceutical licensed its worldwide development and sales rights to Jassen in November 2015, excluding China and Korea. Jassen is currently conducting a Phase 2 global clinical trial evaluating the efficacy of HM12325A in 440 obese patients.
“It is now possible to accelerate the development of innovative biomarkers for simultaneous treatment of obesity and diabetes with the global 2nd phase of high obesity patients with diabetes. We will work closely with Jassen so that HM12525A can be commercialized as soon as possible,” said Kwon Se-chang, President of Hanmi Pharmaceutical.
